In addition to receiving a nearly 3% increase in budget over initial proposals from congressional committees, FDA also will see the rare pediatric disease priority review voucher program continue in the new budget deal.
The omnibus appropriations bill, posted early Dec. 16, would provide $4
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?